Study Background and Disease Burden
Septic shock remains a leading cause of mortality in critically ill patients worldwide. It is characterized by profound circulatory, cellular, and metabolic abnormalities leading to organ dysfunction. Persistent hypoperfusion despite standard resuscitation is a critical problem that worsens organ failure and survival. Microcirculatory disturbances in septic shock contribute to tissue hypoxia and organ damage. Iloprost, a prostacyclin analogue, has shown potential in preclinical and small-scale clinical studies for improving microvascular blood flow and tissue perfusion, possibly attenuating organ injury. However, its effect on organ failure outcomes and mortality in septic shock patients with persistent hypoperfusion remained unknown prior to this large randomized trial.
Study Design
This multicenter, double-blind, placebo-controlled randomized clinical trial enrolled 240 adults diagnosed with septic shock exhibiting persistent hypoperfusion, defined by increased capillary refill time and/or skin mottling despite adequate initial resuscitation. Participants were randomized to receive a 48-hour intravenous infusion of iloprost or matching placebo. The primary endpoint was the change in Sequential Organ Failure Assessment (SOFA) score from baseline to day 7, a validated surrogate for organ dysfunction severity. Secondary endpoints included mortality at 28 days, organ support-free days (ventilation, vasopressors, renal replacement therapy), and mean daily SOFA scores during follow-up. Safety outcomes focused on the incidence of severe adverse events.
Key Findings
Out of 240 randomized patients, 236 were included in the analysis. The median change in SOFA score from randomization to day 7 was -4 (IQR: -7 to 7) in the iloprost group and -5 (IQR: -8 to 5) in the placebo group, with a non-significant median difference of 1 (95% CI: 0 to 3, P=0.12). Mortality at 28 days was similar between groups: 42% in the iloprost group versus 39% in the placebo group (relative risk 1.08; 95% CI, 0.80–1.5). Secondary endpoints, including mean SOFA scores and organ support-free survival days, showed no meaningful difference between groups. Notably, severe adverse events trended higher in the iloprost group (15%) compared to placebo (7%), although this did not reach statistical significance (P=0.06).
Expert Commentary
This study provides robust evidence from a rigorous randomized controlled trial that iloprost infusion over 48 hours does not confer organ protection or survival benefits in adults with severe septic shock and persistent hypoperfusion. The pathophysiology of septic shock-induced organ failure involves multifactorial mechanisms beyond microcirculatory impairment, which may explain the lack of efficacy despite iloprost’s theoretical benefits. The higher incidence of severe adverse events in the iloprost arm warrants caution and suggests potential safety concerns, although further investigation is needed. The trial’s strengths include adequate sample size, rigorous blinding, and relevant patient selection criteria, but limitations include the inability to detect subtle microcirculatory improvements without direct measurement and unknown long-term effects. Future research might explore combination therapies targeting different pathogenic pathways or utilize biomarkers to identify responder subgroups.
Conclusion
In summary, this landmark randomized trial concludes that iloprost does not reduce organ failure severity or improve mortality in patients with septic shock and persistent hypoperfusion. These findings emphasize the complexity of septic shock pathogenesis and the challenges in translating promising mechanistic therapies into clinical benefit. Clinicians should continue to rely on evidence-based supportive care while ongoing research seeks novel therapeutic strategies to improve outcomes in this high-risk population.
References
Legrand M, Jullien E, Kimmoun A, et al; I-MICRO Trial Investigators. Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial. Am J Respir Crit Care Med. 2025 Jul;211(7):1211-1219. doi: 10.1164/rccm.202410-1924OC. PMID: 40387381; PMCID: PMC12264687.
